On this episode of the She’s Healthy podcast your host and Nurse Practitioner, Lori Aikman, looks at the research to see…

Which is better for weight loss semaglutide (Wegovy) or tirzepatide (Zepbound)?

If you're a woman who is struggling to lose weight, maybe all the things you used to do like diet and exercise aren't working and you're looking for more. If you're considering taking one of these medications to help your stubborn weight loss, this is an episode you won't want to miss.
Key Takeaways:

Mechanism of Action: Lori reviews how both semaglutide and tirzepatide work to induce weight loss. If you missed the details, check out the first episode for an indepth discussion.
Approval Timeline: Semaglutide received FDA approval for treating obesity before tirzepatide. Tirzepatide was FDA approved for obesity on 11/8/23.
Clinical Trials: Explore the results of the STEP trials, focusing on semaglutide's effectiveness for obesity. Learn about the SURPASS trials that studied tirzepatide's impact on patients with diabetes, and get a sneak peek into the upcoming SURMOUNT trials examining tirzepatide's efficacy for obesity in both diabetic and nondiabetic patients.
Pharmaceutical Source: Both semaglutide and tirzepatide injections are products of the renowned pharmaceutical company, Eli Lilly.
Prescribing Guidelines: Understand the obesity prescribing guidelines, emphasizing that these medications are intended for individuals with a BMI greater than 30 or a BMI greater than 27 with weightrelated comorbidities such as diabetes, prediabetes, high blood pressure, high cholesterol, cardiovascular disease, etc.
SURMOUNT1 Trial: Delve into the findings of the SURMOUNT1 trial, exploring the effectiveness of various tirzepatide doses compared to a placebo for weight loss. Discover that weight loss increases with higher doses of tirzepatide.
Comparison Study: Gain insights from the study "Weight loss with subcutaneous semaglutide versus other glucagonlike peptide 1 receptor agonists in type 2 diabetes." Find out how tirzepatide outperformed semaglutide, dulaglutide, exenatide, and liraglutide in terms of weight loss.
Appetite Reduction: Uncover takeaways from the study "Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes."
CostEffective Options: Lori suggests a costeffective alternative – getting these medications from a compounding pharmacy.


Whether you're on a weight loss journey or simply curious about these medications, Lori provides valuable insights to guide your decisions. Tune in to the She’s Healthy podcast and stay informed about optimizing your health in your 30s and 40s!

Curious about working with Lori? Click here to book a 15 Minute Connection Call: https://crownexecutivehealth.practice...

Check out the website: http://www.queenbeemedicine.com

Follow us on Instagram:
  / queenbeemedicine  
  / loriaikman